Welcome to our dedicated page for BDR news (Ticker: BDR), a resource for investors and traders seeking the latest updates and insights on BDR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BDR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BDR's position in the market.
Blonder Tongue Laboratories, Inc. (NYSE American: BDR) will report its Second Quarter 2021 Earnings Results on August 12, 2021, before market opening. Following the release, management will host a teleconference at 11:00 a.m. ET for analysts and investors to discuss the results. The company emphasizes its long-standing position in cable television video transmission technology and aims to deliver high-reliability solutions for digital video and data services.
Blonder Tongue Laboratories (NYSE American: BDR) announced the forgiveness of a PPP Loan totaling $1,768,762, which was received under the Paycheck Protection Program initiated by the CARES Act. The loan, originally received on April 10, 2020, was aimed at supporting the company during the COVID-19 pandemic. Approval from the SBA and the lender was confirmed on June 30, 2021, and the impact of this forgiveness will be reflected in the second quarter financials. CFO Eric Skolnik stated the loan was crucial for maintaining operations during a challenging market period.
Blonder Tongue Laboratories (NYSE American: BDR) has partnered with Innovative Systems to enhance its NXG IP Digital Video Signal Processing Platform. This advancement allows businesses to upgrade their video offerings while significantly reducing operating costs and the need for new hardware. The flexible NXG platform supports various video formats, is cost-effective, and enables seamless integration into existing infrastructures. Notable features include enhanced encryption for secure video services and remote management capabilities, making deployment efficient and customizable for specific property needs.
Blonder Tongue Laboratories, Inc. (NYSE American: BDR) reported a 19.7% decline in net sales for Q1 2021, totaling $3,251,000, compared to $4,050,000 in Q1 2020. The company incurred a net loss of $(414,000) or $(0.04) per share, an improvement from $(2,080,000) or $(0.21) per share year-over-year. Positive cash flow from operations was $234,000, up from a $(842,000) cash outflow in the prior year. The gross margin improved significantly to 42.6%, driven by enhanced operational efficiency and a favorable product mix, despite ongoing concerns about liquidity and the company's ability to continue as a going concern.
Blonder Tongue Laboratories, Inc. (NYSE American:BDR) will announce its First Quarter 2021 Earnings results on May 13, 2021, before the market opens. A teleconference is scheduled for 11:00 a.m. ET to discuss the results. Investors can access the call by dialing 888-506-0062 with entry code 591489. Blonder Tongue is a longstanding leader in cable video transmission technology, offering reliable products designed in their New Jersey facility. The company emphasizes ongoing commitment to engineering excellence and operational reliability.
Blonder Tongue Laboratories, Inc. (NYSE American: BDR) has received a notice of noncompliance from NYSE American due to stockholders' equity of only $1,237,000 as of December 31, 2020, and consistent losses over the last five fiscal years. Previously, the company received similar notices for not meeting other compliance standards. Blonder Tongue submitted a financial plan to regain compliance by December 10, 2021, but has struggled due to COVID-19 impacts, raising concerns about potential delisting if it fails to meet the standards.
Blonder Tongue Laboratories reported a 14.2% decline in net sales for Q4 2020, totaling $4.3 million, with a net loss of $2.4 million or $(0.23) per share. For the full year, sales fell 17.5% to $16.4 million, with a net loss of $(7.5 million) or $(0.76) per share. The company implemented significant operational restructuring, reducing costs by $940,000 in 2020. Key developments include over 15 new product introductions and a 35% increase in sales efforts towards telecom relationships. Despite challenges, the company aims for growth in 2021.
Blonder Tongue Laboratories, Inc. (NYSE American: BDR) will announce its Fourth Quarter and Year End 2020 Earnings Results on March 12, 2021, before market opening. Following the earnings report, a teleconference will be held at 11:00 a.m. ET to discuss the results with investors. Interested parties can join the call at 888-506-0062 using the entry code 762058. The audio replay will be accessible on the company's Investor Relations webpage. Blonder Tongue, a leader in cable television technology, has been operational for over 50 years.
Blonder Tongue Laboratories, Inc. (NYSE American:BDR) announced its 2021 Annual Meeting of Stockholders to take place on May 26, 2021, at 10:00 a.m. at their headquarters in Old Bridge, NJ. Eligible voters must be stockholders as of April 15, 2021. Established over 50 years ago, Blonder Tongue is a leading designer and manufacturer of telecommunications technology, focusing on digital video and broadband distribution services. The company emphasizes U.S.-based engineering excellence and robust product reliability.
Blonder Tongue Laboratories, Inc. (NYSE American: BDR) announced a Securities Purchase Agreement on December 14, 2020, for a private placement of 1,428,571 shares of Common Stock and warrants to purchase 714,286 additional shares. The Company expects to receive $1 million in gross proceeds, aimed at enhancing liquidity for R&D and product introductions in 2021. The private placement includes fully-vested and contingent warrants for placement agents. The shares sold will not be registered under the Securities Act of 1933, but the Company plans to file a registration statement for resale.
FAQ